{"id":6875,"date":"2021-10-06T09:32:12","date_gmt":"2021-10-06T07:32:12","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf"},"modified":"2021-10-06T09:32:12","modified_gmt":"2021-10-06T07:32:12","slug":"vedanta-announces-positive-topline-phase-2-data-for-ve303-in-high-risk-c-difficile-infection-and-exercise-of-23-8-million-option-by-barda-_-business-wire","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/vedanta-announces-positive-topline-phase-2-data-for-ve303-in-high-risk-c-difficile-infection-and-exercise-of-23-8-million-option-by-barda\/vedanta-announces-positive-topline-phase-2-data-for-ve303-in-high-risk-c-difficile-infection-and-exercise-of-23-8-million-option-by-barda-_-business-wire\/","title":{"rendered":"Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA _ Business Wire"},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-6875","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA _ Business Wire | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf\",\"name\":\"Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA _ Business Wire | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2021-10-06T07:32:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA\",\"item\":\"https:\/\/www.seventure.fr\/en\/vedanta-announces-positive-topline-phase-2-data-for-ve303-in-high-risk-c-difficile-infection-and-exercise-of-23-8-million-option-by-barda\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA _ Business Wire\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA _ Business Wire | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf","name":"Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA _ Business Wire | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2021-10-06T07:32:12+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA","item":"https:\/\/www.seventure.fr\/en\/vedanta-announces-positive-topline-phase-2-data-for-ve303-in-high-risk-c-difficile-infection-and-exercise-of-23-8-million-option-by-barda\/"},{"@type":"ListItem","position":3,"name":"Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA _ Business Wire"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf'><img loading=\"lazy\" decoding=\"async\" width=\"232\" height=\"300\" src=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf-232x300.jpg\" class=\"attachment-medium size-medium\" alt=\"\" \/><\/a><\/p>\n"},"caption":{"rendered":""},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{"sizes":{"thumbnail":{"file":"Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf-116x150.jpg","width":116,"height":150,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf-116x150.jpg"},"medium":{"file":"Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf-232x300.jpg","width":232,"height":300,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf-232x300.jpg"},"large":{"file":"Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf-791x1024.jpg","width":791,"height":1024,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf-791x1024.jpg"},"full":{"file":"Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf.jpg","width":1086,"height":1406,"mime_type":"application\/pdf","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire-pdf.jpg"}}},"post":6874,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA-_-Business-Wire.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/6875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=6875"}]}}